What are the treatment options for severe pruritus in a patient with restless‑legs syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Severe Pruritus in RLS Patients

Start with gabapentin or pregabalin as first-line therapy for your RLS patient's terrible itching, as these alpha-2-delta ligands are now the primary recommended treatments for RLS and may address both the movement disorder and associated sensory symptoms. 1

Understanding the Clinical Picture

The "terrible itching" you describe is likely part of the RLS symptom complex itself—RLS characteristically presents with dysesthesias (uncomfortable sensations) in the affected extremities that patients may describe as itching, crawling, or other unpleasant sensations. This is distinct from true dermatologic pruritus. The key diagnostic feature is that these sensations are relieved by movement and worsen with immobility, particularly in the evening/night 1.

First-Line Treatment Algorithm

Step 1: Check Iron Status Immediately

  • Measure ferritin and transferrin saturation
  • If ferritin < 75 ng/mL: Treat with iron supplementation to achieve ferritin > 100 ng/mL 1, 2
    • IV ferric carboxymaltose receives the strongest recommendation (strong recommendation, moderate certainty) 1
    • Oral ferrous sulfate is an alternative (conditional recommendation) but poorly absorbed if ferritin > 50-75 ng/mL 1

Step 2: Initiate Alpha-2-Delta Ligand Therapy

The 2025 AASM guidelines provide strong recommendations for:

  • Gabapentin (strong recommendation, moderate certainty) 1
  • Pregabalin (strong recommendation, moderate certainty) 1

These agents address the core RLS pathophysiology and should improve the dysesthetic symptoms (the "itching") along with the urge to move.

Critical Pitfall: Avoid Dopamine Agonists

Do NOT use dopamine agonists (pramipexole, ropinirole, rotigotine) as standard therapy 1. The 2025 guidelines represent a major paradigm shift—these agents are now conditionally recommended against for standard use due to the high risk of augmentation (worsening of symptoms with long-term use) 1, 3. This is a dramatic reversal from 2012 guidelines where they were first-line 1, 4.

Additional Treatment Options

If Inadequate Response to First-Line Therapy:

  • Extended-release oxycodone or other opioids (conditional recommendation, moderate certainty) 1

    • Particularly useful if augmentation from prior dopamine agonist use
    • Monitor for respiratory depression, especially with concurrent sleep apnea 1
  • Bilateral high-frequency peroneal nerve stimulation (conditional recommendation, moderate certainty) 1

    • Can serve as adjunct therapy in refractory cases 4

Medications to Avoid:

  • Do NOT use: Cabergoline (strong recommendation against) 1
  • Do NOT use: Bupropion, carbamazepine, clonazepam, valproic acid (all conditional recommendations against) 1

Special Consideration: True Pruritus vs RLS Dysesthesia

If you suspect the itching is true dermatologic pruritus rather than RLS dysesthesia, gabapentin remains appropriate as it's recommended for neuropathic pruritus 5. However, the presence of RLS makes this distinction less critical since gabapentin addresses both conditions.

If Patient Has End-Stage Renal Disease

The treatment approach differs slightly:

  • Gabapentin still recommended (conditional recommendation) 1
  • IV iron sucrose if ferritin < 200 ng/mL and transferrin saturation < 20% (conditional recommendation) 1
  • Consider vitamin C supplementation (conditional recommendation) 1

Implementation Strategy

  1. Today: Order ferritin and transferrin saturation
  2. Today: Start gabapentin (titrate to effect) or pregabalin
  3. When labs return: Add IV ferric carboxymaltose if ferritin < 75 ng/mL
  4. Reassess in 2-4 weeks: If inadequate response, consider adding opioid therapy or referral for device-based treatment

The evidence strongly supports this iron-conscious, alpha-2-delta ligand-first, augmentation-aware approach as the modern standard of care 3, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.